Compare Mesoblast Limited (MESO) vs Uranium Energy Corp (UEC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Uranium Energy Corp — how do they compare? Mesoblast Limited trades at $13.8 (market cap $1.75B), while Uranium Energy Corp trades at $9.38 (market cap $4.53B). The key difference: Uranium Energy Corp is far larger — about 2.6× Mesoblast Limited's market cap, and Mesoblast Limited is more actively traded (239,027 versus 10,888,578). Which is the better fit depends on your goals — on Pluang, investors hold Mesoblast Limited for 14 Days and Uranium Energy Corp for 37 Days on average.
| MESO | UEC | |
|---|---|---|
Market Cap | $1.75B | $4.53B |
Volume | 239,027 | 10,888,578 |
Sector | Health | Energy |
52-Week High | $20.96 | $20.14 |
52-Week Low | $13.19 | $9.04 |
Typical Hold Time | 14 Days | 37 Days |
Enterprise Value | $1.83B | $4.03B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $13.94, up 2.42% with bearish technical signals from moving averages. The company reported substantial revenue growth to $120 million in 2026 but remains unprofitable with a -47.82% net margin. Recent FDA approval for Ryoncil potency assay and completion of Phase 3 back pain trial represent significant operational milestones. Cash position remains strong at $161.16 million, though debt levels require monitoring.
While MESO shows promising revenue growth and pipeline progress, persistent losses and negative ROE present fundamental challenges. Analyst consensus leans bullish with 45% buy ratings, but technical indicators suggest near-term caution. The stock offers speculative growth potential contingent on successful commercialization and path to profitability.
Uranium Energy (UEC) trades at $9.47, down 6.33% today, amid bearish technical signals despite strong analyst support. The stock shows negative profitability with a net income margin of -368.62% and has missed earnings expectations in recent quarters. However, the company is expanding production capacity with two operational mines and benefits from growing U.S. government demand for domestic uranium.
While analyst consensus remains strongly bullish with an 87.5% buy rating and $16.06 price target, fundamental challenges persist including negative cash flow from operations and unproven production sustainability. The stock faces execution risks as it scales operations, but long-term uranium demand tailwinds provide potential upside if operational improvements materialize.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Uranium Energy Corp
Uranium Energy Corp is a leading American uranium mining and exploration company, currently holding the largest resource base and licensed production capacity in the United States. Utilizing low-cost, environmentally friendly In-Situ Recovery (ISR) mining, UEC is a central player in the domestic nuclear fuel supply chain, transitioning from a resource holder to an active producer and refiner to meet the accelerating demand for carbon-free energy.
Read more on UEC →
